相关实验视频

Updated: Jun 22, 2025

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

基于血小板膜仿生向纳米技术的联合药物抗深静脉血栓症治疗

Hang Xiao¹, Xiangrui Meng², Songtao Li²

¹The Key Laboratory of TCM Collateral Disease Theory Research, School of Traditional Chinese Medicine, Capital Medical University, Beijing, 100069, PR China.

|June 28, 2024

概括

这项研究引入了一种用于深静脉血栓塞 (DVT) 治疗的新型纳米平台,在半剂量下有效提供抗凝剂. 有针对性的方法提高了生物相容性,并减少了与传统疗法相关的出血风险.

科学领域:

生物医学工程生物医学工程
纳米技术纳米技术
药理学药理学是指药理学的学科.

背景情况:

整形外科手术增加深静脉血栓塞 (DVT) 的风险,这种情况通常用抗凝固药物治疗,有出血风险.
目前的DVT治疗需要高剂量的药物,增加潜在的有毒副作用和出血并发症.

研究的目的:

使用血小板衍生纳米平台开发针对性药物输送系统用于DVT治疗.
为了同时提供复合希鲁丁 (rH) 和阿皮克萨班 (A),以增强DVT病变的消除.
为了评估纳米平台的生物相容性,血液半衰期,以及降低剂量的治疗疗效.

主要方法:

开发了被血小板膜 (PM) 覆盖的氨基化半孔纳米颗粒 (AMSNP),用于向的DVT输送 (AMSNP@PM-rH/A).
同时加载一种直接的血栓抑制剂 (复合希鲁丁,rH) 和一种XA因子抑制剂 (阿皮克萨班,A).
利用可视化技术来追踪DVT地点的纳米平台积累和药物释放.

主要成果:

AMSNP@PM-rH/A纳米平台显示了生物相容性改善和血液半衰期延长.
观察到深静脉血栓瘤病变的有效消除.
使用一半标准药物剂量实现治疗效果,表明疗效提高和毒性降低.

结论:

开发的血小板衍生纳米平台为DVT治疗提供了一个有希望的向药物输送策略.
这种方法有可能减少抗凝剂剂量和相关的出血风险.
这项研究强调了血小板膜涂层纳米颗粒在局部DVT治疗中的潜力.

关键词:

深静脉血栓形成的原因是深静脉血栓.这是一种XA因子抑制剂.血小板衍生的纳米平台.复合希鲁丁是一种重组希鲁丁.视觉化技术是一种可视化技术.

更多相关视频

Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation

Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation

Published on: December 15, 2010

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli

Published on: September 25, 2016

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...